These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38974686)

  • 21. Cognitive and motor function in people with multiple sclerosis in Stockholm County.
    Einarsson U; Gottberg K; von Koch L; Fredrikson S; Ytterberg C; Jin YP; Andersson M; Holmqvist LW
    Mult Scler; 2006 Jun; 12(3):340-53. PubMed ID: 16764349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Working ability in individuals with different disease courses of multiple sclerosis: Factors beyond physical impairment.
    Renner A; Baetge SJ; Filser M; Penner IK
    Mult Scler Relat Disord; 2020 Nov; 46():102559. PubMed ID: 33035965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The relationship between processing speed and verbal and non-verbal new learning and memory in progressive multiple sclerosis.
    Chiaravalloti ND; DeLuca J; Salter A; Amato MP; Brichetto G; Chataway J; Dalgas U; Farrell R; Feys P; Filippi M; Freeman J; Inglese M; Meza C; Moore NB; Motl RW; Rocca MA; Sandroff BM; Cutter G; Feinstein A
    Mult Scler; 2022 Oct; 28(11):1783-1792. PubMed ID: 35531965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both?
    Jakimovski D; Benedict RHB; Weinstock-Guttman B; Ozel O; Fuchs TA; Lincoff N; Bergsland N; Dwyer MG; Zivadinov R
    J Neurol; 2021 Jul; 268(7):2578-2588. PubMed ID: 33590339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis.
    Siddiqui K; Browne RW; Benedict RHB; Jakimovski D; Weinstock-Guttman B; Zivadinov R; Ramanathan M
    Mult Scler Relat Disord; 2023 Jan; 69():104374. PubMed ID: 36403378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered motor plasticity in an acute relapse of multiple sclerosis.
    Wirsching I; Buttmann M; Odorfer T; Volkmann J; Classen J; Zeller D
    Eur J Neurosci; 2018 Feb; 47(3):251-257. PubMed ID: 29285814
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient reported outcomes in a secondary progressive MS cohort related to cognition, MRI and physical outcomes.
    Theodorsdottir A; Nielsen HH; Ravnborg MH; Illes Z
    Mult Scler Relat Disord; 2023 Mar; 71():104550. PubMed ID: 36842312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quadripulse stimulation (QPS).
    Matsumoto H; Ugawa Y
    Exp Brain Res; 2020 Aug; 238(7-8):1619-1625. PubMed ID: 32211927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS).
    Skorve E; Lundervold AJ; Torkildsen Ø; Myhr KM
    Mult Scler Relat Disord; 2019 Nov; 36():101408. PubMed ID: 31610403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recovery of cognitive function after relapse in multiple sclerosis.
    Benedict RH; Pol J; Yasin F; Hojnacki D; Kolb C; Eckert S; Tacca B; Drake A; Wojcik C; Morrow SA; Jakimovski D; Fuchs TA; Dwyer MG; Zivadinov R; Weinstock-Guttman B
    Mult Scler; 2021 Jan; 27(1):71-78. PubMed ID: 31971066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dimethyl fumarate treatment of primary progressive multiple sclerosis: results of an open-label extension study.
    Højsgaard Chow H; Talbot J; Lundell H; Marstrand L; Gøbel Madsen C; Bach Søndergaard H; Bredahl Hansen M; Solberg Sørensen P; Siebner HR; Sellebjerg F
    Mult Scler Relat Disord; 2023 Feb; 70():104458. PubMed ID: 36586351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis.
    Radetz A; Mladenova K; Ciolac D; Gonzalez-Escamilla G; Fleischer V; Ellwardt E; Krämer J; Bittner S; Meuth SG; Muthuraman M; Groppa S
    Front Immunol; 2021; 12():748357. PubMed ID: 34712236
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
    Ryerson LZ; Foley JF; Defer G; Cohen JA; Arnold DL; Butzkueven H; Cutter G; Giovannoni G; Killestein J; Wiendl H; Sinks S; Kuhelj R; Bodhinathan K; Lasky T
    Mult Scler Relat Disord; 2023 Apr; 72():104561. PubMed ID: 36931078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results.
    Wilken J; Traboulsee A; Nelson F; Ionete C; Kolind S; Fratto T; Kane R; Gandhi R; Rawlings AM; Roesch N; Ozog MA; DeLuca J;
    Mult Scler Relat Disord; 2023 May; 73():104677. PubMed ID: 37028124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study.
    Eijlers AJC; van Geest Q; Dekker I; Steenwijk MD; Meijer KA; Hulst HE; Barkhof F; Uitdehaag BMJ; Schoonheim MM; Geurts JJG
    Brain; 2018 Sep; 141(9):2605-2618. PubMed ID: 30169585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel cognitive-behavioral stress management method for multiple sclerosis. A brief report of an observational study.
    Anagnostouli M; Babili I; Chrousos G; Artemiadis A; Darviri C
    Neurol Res; 2019 Mar; 41(3):223-226. PubMed ID: 30451648
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impairment of daily occupations in multiple sclerosis: analysis of neuroimaging, general and social cognition, and reserve.
    Gomes LR; Damasceno BP; de Campos BM; Damasceno A
    Mult Scler Relat Disord; 2024 Jan; 81():105140. PubMed ID: 37988860
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Nine-Hole Peg Test as a manual dexterity performance measure for multiple sclerosis.
    Feys P; Lamers I; Francis G; Benedict R; Phillips G; LaRocca N; Hudson LD; Rudick R;
    Mult Scler; 2017 Apr; 23(5):711-720. PubMed ID: 28206826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive trajectories in multiple sclerosis: a long-term follow-up study.
    Carotenuto A; Costabile T; Pontillo G; Moccia M; Falco F; Petracca M; Petruzzo M; Russo CV; Di Stasi M; Paolella C; Perillo T; Vola EA; Cipullo MB; Cocozza S; Lanzillo R; Brescia Morra V; Saccà F
    Neurol Sci; 2022 Feb; 43(2):1215-1222. PubMed ID: 34105018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project.
    Walker LA; Osman L; Berard JA; Rees LM; Freedman MS; MacLean H; Cousineau D
    J Neurol Sci; 2016 Mar; 362():147-52. PubMed ID: 26944137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.